Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Verrica Pharmaceuticals Inc (VRCA)

Verrica Pharmaceuticals Inc (VRCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,351
  • Shares Outstanding, K 41,094
  • Annual Sales, $ 12,000 K
  • Annual Income, $ -35,080 K
  • 60-Month Beta 2.03
  • Price/Sales 10.48
  • Price/Cash Flow N/A
  • Price/Book 5.16
Trade VRCA with:

Options Overview Details

View History
  • Implied Volatility 116.29% ( -96.10%)
  • Historical Volatility 97.66%
  • IV Percentile 62%
  • IV Rank 13.50%
  • IV High 431.82% on 06/16/22
  • IV Low 67.07% on 02/15/22
  • Put/Call Vol Ratio 0.46
  • Today's Volume 133
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 2,602
  • Open Int (30-Day) 1,987

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.23
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +76.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.60 +10.77%
on 09/23/22
4.47 -35.50%
on 09/13/22
-0.55 (-16.03%)
since 08/23/22
3-Month
1.79 +60.89%
on 06/30/22
4.47 -35.50%
on 09/13/22
+0.63 (+28.00%)
since 06/23/22
52-Week
1.77 +62.71%
on 06/01/22
13.64 -78.89%
on 10/15/21
-8.95 (-75.66%)
since 09/23/21

Most Recent Stories

More News
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of...

VRCA : 2.88 (-5.88%)
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

JAZZ : 127.67 (-2.23%)
CPRX : 11.87 (-2.70%)
AERI : 15.12 (-0.13%)
VRCA : 2.88 (-5.88%)
VRCA SHAREHOLDER ALERT: Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Verrica Pharmaceuticals, Inc....

VRCA : 2.88 (-5.88%)
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceuticals...

VRCA : 2.88 (-5.88%)
Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Verrica Pharmaceuticals Inc. (VRCA) Investors of Class Action and Last Few Hours to Actively Participate

Attorney Advertising-Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ:...

VRCA : 2.88 (-5.88%)
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y

Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.

MRK : 86.78 (-0.83%)
CORT : 25.08 (-0.52%)
VRCA : 2.88 (-5.88%)
TCRT : 1.7300 (-7.98%)
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up

Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.

NBIX : 103.50 (+0.15%)
ZTS : 150.05 (+0.39%)
IONS : 43.23 (-3.87%)
VRCA : 2.88 (-5.88%)
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.

PCRX : 52.86 (-2.02%)
AQST : 1.0900 (+1.87%)
VRCA : 2.88 (-5.88%)
TCRT : 1.7300 (-7.98%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Verrica Pharmaceuticals...

VRCA : 2.88 (-5.88%)
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”)...

VRCA : 2.88 (-5.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States.

See More

Key Turning Points

3rd Resistance Point 3.49
2nd Resistance Point 3.25
1st Resistance Point 3.07
Last Price 2.88
1st Support Level 2.65
2nd Support Level 2.41
3rd Support Level 2.23

See More

52-Week High 13.64
Fibonacci 61.8% 9.11
Fibonacci 50% 7.70
Fibonacci 38.2% 6.30
Last Price 2.88
52-Week Low 1.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar